Edge Therapeutics, Inc.

Edge Therapeutics is a **clinical-stage biotechnology company** founded in **2009** and based in Berkeley Heights, New Jersey. The company's slogan, "Pioneering novel therapies to dramatically improve outcomes for life-threatening neurological conditions," reflects its focus on creating and bringing to market innovative therapies for acute, life-threatening neurological conditions in hospital settings. Their lead product candidate, **EG-1962**, aims to significantly enhance patient outcomes and alter the treatment approach for aneurysmal subarachnoid hemorrhage (aSAH), while their second product candidate, **EG-1964**, is under evaluation as a preventive treatment for chronic subdural hematoma. The company successfully raised a significant **$56.00M Series C investment** on **09 April 2015** from a notable group of investors including **New Leaf Venture Partners, Venrock, Sofinnova Investments, Franklin Advisors, BioMed Ventures, and Janus Capital Group**. With its strategic focus on developing therapies for critical neurological conditions and a strong backing from prominent investors, Edge Therapeutics is positioned to make significant contributions to the biotechnology and healthcare industries.